Carisma Therapeutics Announces Changes to its Board of Directors

CARM 10.30.2024

Full Press ReleaseSEC FilingsOur CARM Tweets

About Gravity Analytica

Recent News

  • 12.09.2024 - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
  • 12.05.2024 - 7th Annual Evercore ISI HealthCONx Conference
  • 11.27.2024 - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.02.2025 - 3 Initial statement of beneficial ownership of securities
  • 11.07.2024 - EX-99.1 EX-99.1

Appointment of Sohanya Cheng

Resignation of Michael Torok

PHILADELPHIA,Oct. 30, 2024/PRNewswire/ --Carisma Therapeutics Inc.(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effectiveOctober 31, 2024. Additionally,Michael Torokhas informed the Board of his intention to step down as a member, effectiveOctober 31, 2024, due to other professional commitments.

(PRNewsfoto/CARISMA Therapeutics Inc.)

"It's a pleasure to welcome Sohanya to our Board," saidSanford Zweifach, Chair of the Carisma Board. "Her broad experience in oncology, alongside her skills in leadership, strategic planning, and commercialization, will be instrumental as we continue to advance our portfolio and strengthen our foundation. We are also thankful to Michael for his valuable service and wish him all the best in his next chapter."

"I am excited to join Carisma's Board and collaborate with the management team as the Company advances its mission to deliver innovative immunotherapies to patients facing serious diseases," saidMs. Cheng. "Ilook forward to sharing my insights and supporting the Company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond."

About Sohanya Cheng, MBA

Ms. Chengbrings over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. She currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics. Prior to this, she was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals.Ms. Chengalso spent over a decade at Amgen in various leadership roles, including Executive Director, Head of Marketing & Sales for multiple myeloma and Head of Oncology National Sales, contributing to the commercialization of key oncology brands. She holds an MBA from theMIT Sloan School of Managementand both a BSc and MA from the University ofCambridge, UK.

About Carisma

Carisma Therapeutics Inc.is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered inPhiladelphia, PA.For more information, please visitwww.carismatx.com.

Investors:Shveta DigheHead of Investor Relationsinvestors@carismatx.com

Media Contact:Julia Stern(763) 350-5223jstern@realchemistry.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302292071.html

SOURCECarisma Therapeutics Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com